Soligenix, Inc. (SNGX)
0.3602
+0.01
(+2.88%)
USD |
NASDAQ |
Oct 22, 11:01
Soligenix Enterprise Value : -1.933M for Oct. 21, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 21, 2026 | -1.933M |
| October 20, 2026 | -1.836M |
| October 19, 2026 | -2.072M |
| October 16, 2026 | -1.868M |
| October 15, 2026 | -1.825M |
| October 14, 2026 | -2.137M |
| October 13, 2026 | -2.264M |
| October 12, 2026 | -1.899M |
| October 09, 2026 | -1.641M |
| October 08, 2026 | -2.009M |
| October 07, 2026 | -1.860M |
| October 06, 2026 | -1.762M |
| October 05, 2026 | -1.741M |
| October 02, 2026 | -1.602M |
| October 01, 2026 | -1.637M |
| September 30, 2026 | -1.676M |
| September 29, 2026 | -1.611M |
| September 28, 2026 | -1.342M |
| September 25, 2026 | -1.193M |
| September 24, 2026 | -1.152M |
| September 23, 2026 | -1.176M |
| September 22, 2026 | -1.178M |
| September 21, 2026 | -1.459M |
| September 18, 2026 | -1.503M |
| September 17, 2026 | -1.392M |
| Date | Value |
|---|---|
| September 16, 2026 | -1.719M |
| September 15, 2026 | -1.717M |
| September 14, 2026 | -1.702M |
| September 11, 2026 | -1.632M |
| September 10, 2026 | -1.717M |
| September 09, 2026 | -1.568M |
| September 08, 2026 | -1.332M |
| September 04, 2026 | -1.286M |
| September 03, 2026 | -1.217M |
| September 02, 2026 | -1.250M |
| September 01, 2026 | -1.373M |
| August 31, 2026 | -1.286M |
| August 28, 2026 | -1.356M |
| August 27, 2026 | -1.286M |
| August 26, 2026 | -1.200M |
| August 25, 2026 | -0.7431M |
| August 24, 2026 | -0.7518M |
| August 21, 2026 | -0.8319M |
| August 20, 2026 | -1.284M |
| August 19, 2026 | -1.262M |
| August 18, 2026 | -0.94M |
| August 17, 2026 | -1.260M |
| August 14, 2026 | -0.8535M |
| August 13, 2026 | -1.267M |
| August 12, 2026 | -1.070M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.593B |
| Alnylam Pharmaceuticals, Inc. | 29.78B |
| Anika Therapeutics, Inc. | 262.53M |
| Savara, Inc. | 816.59M |
| Vericel Corp. | 2.027B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.987M |
| Total Expenses (Quarterly) | 1.987M |
| EPS Diluted (Quarterly) | -0.1246 |
| Earnings Yield | -353.8% |
| Normalized Earnings Yield | -354.47 |